Internal Medicine, Endocrinology, Diabetes, & Metabolism · Beverly Hills, CA
NPI
1972921922
Since 2014
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
99 N la Cienega Blvd Ste 107
Beverly Hills, CA, 90211
Phone (310) 652-5292
Groups this clinician bills Medicare through
Medicare paid, 2024
$591K
6,946 services
Medicare patients, 2024
1,116
Average age 73
Drug cost, 2024
$2.1M
4,173 prescriptions
Company payments, 2025
$3,927
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Albert Shamouelian was code 99232 (hospital e&m - subsequent), 2,573 times for 469 patients. In total Albert Shamouelian billed 6,946 services in 31 codes, and Medicare paid $591K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 2,573 | 469 | $64.84 | $167K |
| 99233 Hospital E&M - Subsequent | Facility | 1,533 | 467 | $97.62 | $150K |
| 99223 Hospital E&M - Initial | Facility | 579 | 471 | $142.50 | $83K |
| 99214 Office E&M - Established | Office | 541 | 326 | $108.45 | $59K |
| 83036 Blood Count | Office | 369 | 242 | $9.52 | $3,513 |
| 95251 Test - Miscellaneous | Office | 261 | 138 | $28.51 | $7,441 |
| 99443 Telephone Services | Office | 237 | 166 | $110.04 | $26K |
| 99204 Office E&M - New | Office | 213 | 213 | $138.16 | $29K |
| 99215 Office E&M - Established | Office | 199 | 157 | $154.56 | $31K |
| 99205 Office E&M - New | Office | 85 | 85 | $181.27 | $15K |
| 82947 Clinical Chemistry | Office | 79 | 67 | $3.85 | $304 |
| 95250 Test - Miscellaneous | Office | 55 | 52 | $136.24 | $7,493 |
| 36415 Venipuncture Blood Collection | Office | 41 | 39 | $8.65 | $355 |
| 76536 Ultrasound - Nonspecific | Office | 35 | 33 | $100.30 | $3,510 |
| 99203 Office E&M - New | Office | 27 | 27 | $88.02 | $2,377 |
By year: 2022 $90K for 1,030 services; 2023 $397K for 4,339 services; 2024 $591K for 6,946 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 369 | 242 | $9.52 | $3,513 |
| 82947 Clinical Chemistry | 79 | 67 | $3.85 | $304 |
| 36415 Venipuncture Blood Collection | 41 | 39 | $8.65 | $355 |
| 83037 Blood Count | 23 | 22 | $9.52 | $219 |
Medicare prescription drug claims, 2024
In 2024, the drug Albert Shamouelian prescribed most often to Medicare patients was Ozempic (Semaglutide), with 470 prescriptions and refills. In total Albert Shamouelian wrote 4,173 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 470 | 509 | 80 | $463K |
| Jardiance Empagliflozin | 227 | 517 | 92 | $290K |
| Nateglinide Generic | 226 | 500 | 87 | $12K |
| Metformin Hcl Generic | 223 | 522 | 82 | $1,157 |
| Levothyroxine Sodium Generic | 199 | 516 | 67 | $1,890 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 190 | 379 | 82 | $20K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 148 | 324 | 62 | $17K |
| Metformin Hcl Er Metformin Hcl | 145 | 378 | 62 | $1,624 |
| Trulicity Dulaglutide | 134 | 175 | 33 | $162K |
| Mounjaro Tirzepatide | 126 | 128 | 33 | $126K |
| Januvia Sitagliptin Phosphate | 122 | 270 | 49 | $139K |
| Tradjenta Linagliptin | 114 | 217 | 44 | $104K |
| Humalog Kwikpen U-100 Insulin Lispro | 87 | 170 | 38 | $27K |
| Fiasp Flextouch Insulin Aspart (Niacinamide) | 76 | 117 | 27 | $45K |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 66 | 174 | 30 | $27K |
Brand drugs: 2,351 claims; generic drugs: 1,474 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Albert Shamouelian $3,927 ($3,927 in general payments such as food, travel and fees) from 29 companies. The largest payer was Dexcom, Inc. with $379.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 20 | $379 |
| Novo Nordisk Inc NVO | 17 | $371 |
| Corcept Therapeutics CORT | 13 | $356 |
| Abbott Laboratories ABT | 13 | $309 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $275 |
| Mannkind Corporation MNKD | 20 | $268 |
| Recordati_rare_diseases_inc. | 19 | $267 |
| Abbvie Inc. ABBV | 10 | $237 |
| Madrigal Pharmaceuticals MDGL | 12 | $220 |
| Lilly USA, LLC LLY | 11 | $183 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.